Glioblastoma, cancer stem cells and hypoxia

Eli E. Bar

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


Glioblastoma (GBM) prognosis remains dismal, with most patients succumbing to disease within 1 or 2 years of diagnosis. Recent studies have suggested that many solid tumors, including GBM, are maintained by a subset of cells termed cancer stem cells (CSCs). It has been shown that these cells are inherently radio- and chemotherapy resistant, and may be maintained in vivo in a niche characterized by reduced oxygen tension (hypoxia). This review examines the recently described effects of hypoxia on CSC in GBM, and the potential promise in targeting the hypoxic pathway therapeutically.

Original languageEnglish (US)
Pages (from-to)119-129
Number of pages11
JournalBrain Pathology
Issue number2
StatePublished - Mar 2011


  • cancer stem cells
  • CD133
  • digoxin
  • glioma
  • HIF
  • hypoxia
  • side population

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine
  • Clinical Neurology


Dive into the research topics of 'Glioblastoma, cancer stem cells and hypoxia'. Together they form a unique fingerprint.

Cite this